Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a prominent player in the biotechnology industry with a market capitalization of $122.8 billion, recently sold shares of the company’s common stock, according to a recent SEC filing. The stock has shown strong momentum, gaining nearly 18% year-to-date. On February 27, Tatsis sold 530 shares at a price of $475.34 each, totaling approximately $251,930. This transaction was executed under a pre-established trading plan, as noted in the filing. According to InvestingPro analysis, the stock is currently trading near its Fair Value, with 12 more exclusive insights available to subscribers.
Prior to this sale, Tatsis disposed of 4,962 shares on February 26 through a separate transaction priced at $479.61 per share. Following these transactions, Tatsis holds 58,539 shares of Vertex Pharmaceuticals.
These transactions are part of Tatsis’ ongoing management of her equity in the company, with the sales executed under a Rule 10b5-1 trading plan established in February 2024.
In other recent news, Vertex, Inc. reported its financial results for the fourth quarter, showing adjusted earnings per share of $0.15, slightly above the analyst estimate of $0.14. The company’s revenue for the quarter reached $178.5 million, surpassing the consensus of $176.9 million and marking a 15.2% increase year-over-year. However, the company’s guidance for the first quarter of 2025 fell short of expectations, with projected revenue between $175 million and $178 million, below the analyst forecast of $180.3 million. For the full year 2025, Vertex anticipates revenue between $760 million and $768 million, aligning with the consensus estimate of $764 million.
The company also reported a 27% year-over-year increase in cloud revenues, reaching $76.9 million in the fourth quarter, while Annual Recurring Revenue grew by 17.7% to $603.1 million. Vertex plans to invest an additional $14-16 million in research and development for AI initiatives and emerging technologies, aiming to drive long-term growth. Despite the positive full-year outlook, the soft first-quarter guidance has drawn investor attention. These developments highlight Vertex’s strategic focus on leveraging its business model for sustainable growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.